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A controlled double-blind crossover trial of Orudis, a non-
steroid anti-inflammatory drug, has been car.ried out in 98
patients with osteo-arthritis of the knee. The new
preparation was tested against placebo (27 patients),
paracetamol (42 patients) and acetylsalicylic acid (29
patients). It showed statistically significant superiority
over placebo (P<O,05). Compared with paracetamol, the
over-all results showed a marked trend in favour of
Orudis, though this did not reach statistical significance
(0,1> P> 0,05). On the principal criteria for assessment
there was no significant difference between Orudis and
high-dosage salicylate (P<O,05); most of the patients,
however, favoured the former.
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joint, moreover, is not nearly as amenable to reconstructive
or replacement surgery as the hip joint; the result is that,
as long as the joint remains stable, osteo-arthritis of
either the pateIlofemoral or the tib:ofemoral compart-
ments is frequently managed by long-term analgesic and
anti-inflammatory therapy. If this is to be the treatment
of choice, the need for a drug with clear-cut anti-inflamma-
tory and analgesic properties, unaccompanied by intoler-
ab~e side-effects, is manifest.
Previous studies have shown that Orudis, 2-(3-belUoyl-
phenyl) propionic acid, has marked anti-inflammatory and
analgesic activities in experimental animals: is well tole-
rated by man, and is therapeutically useful in the
managem~nt of rheumatoid arthritis and osteo-arthritis of
the hip.'·' In the present article we report the remits of
a controlled therapecrt;c trial of Orudis in 98 patients with
osteo-arthritis of the knee.
The use of systemic or intra-articuiar anti-inflammatory
agents for the treatment of osteo-arthritis of the knee is
based on the belief that the symptoms are in some Trial Design
measure due to an associated synovitis. The arthritic knee-
METHODS




Date received: I March 1974.
Orudis was tested against three separate preparations:
placebo, paracetamol and acetylsalicylic acid. It was
intended that this should establish not only the oVt:r-all
efficacy of the drug, but its relative potency in
comparison with (a) a simple analgesic, and (b) a known
anti-inflammatory agent.
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In each section of the trial a double-blind crossover
technique was used, the same patient having one week
of treatment with each drug in turn. Assessments were
carried out at the beginning of the trial and again after
each 7-day treatment period. The results were plotted on
a sequential analysis chart, only positive preferences for
one or other drug being recorded.
Patients
The same investigator completed each trial period; his
preference for either of the two coded medications used
in the patient was established by a simple majority of the
principal criteria in favour of one or other drug. Over-
all superiority of one drug over another was indicated by
an appropriate breakthrough on the sequential analysis
chart. In addition, each patient was asked to express his
own subjective preference for either of the two medications.
Details of side-effects were carefully recorded after each
medication period.
Ninety-eight patients with osteo-arthritis of one or both
knees completed the trial. There were 8\ women and 17
men; their ages ranged from 28 to 78 years, the average
being 53 years. The diagnosis of osteo-arthritis was
established by a combination of clinical features, such
as pain, tenderness, thickening of the joint margins,
crepitus on movement and restricted mobility, together
with the accepted radiological criteria of degenerative
arthritis.' Excluded from the trial were pregnant women,
patients with dyspepsia, hiatus hernia and peptic ulceration,
patients with known intolerance to salicylates, and those
with clinically obvious instability of the knee.
The distribution of patients in the 3 trial groups is
shown in Table 1.




Twenty-seven patients completed this section of the
trial; 14 received Orudis during the first week and placebo
during the second, while 13 received placebo as the first
and Orudis as the second drug.
The investigator's preference, based on a combination
of the 5 principal criteria, is represented in the sequential
analysis chart (Fig. I). Orudis showed a statistically
significant superiority over placebo (P<0,05). In 5 instan-
ces no difference was detected in the response to the two
drugs. Of the remaining 22 patients, 18 showed greater
improvement on Orudis than on placebo.










I , , I
I, I I
I I I , I I
~
I : PLACEBOI ' I
I , I











The two medications in each trial group were presented
in identical form and administered in divided doses after
meals. The daily dose of Orudis was 200 mg, of para-
cetamol 6 g, and of acetylsalicylic acid 5 g.
The order of drug administration was determined from
tab~es of random numbers. After a 'wash-out' period
during which the patient received no medication, each
drug was given for 7 consecutive days, the crossover
occurring without any further 'wash-out' period. No other
analgesic or anti-inflammatory preparations were per-
mitted during the trial; those patients who failed to





Trial group period period Total
Orudis v. placebo 14 13 27
Orudis v. paracetamol 20 22 42
Orudis v. salicylate 15 14 29
Assessment
Fig. 1. Sequential analysis. Orodis shows statistic-.Jlly
significant superiority over placebo (P<O,05).
Assessment was based on 5 principal criteria: (a) the
degree of pain; (b) stiffness; (c) joint tenderness, all graded
as 0 - 3; (d) maximum joint circumference; and (e) strength
of knee extension from 900, measured in kg with a
specially constructed calibrated spring gauge.
The patients ,ubjective preferences also favoured
Orudis, though the difference here was not as marked as
indicated above; 15 preferred Orudis, 10 preferred placebo
and 2 expressed no preference for either.
Four patients complained of side-effects while being
13
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treated with Orudis: 2 experienced dizziness and 2 had
episodes of excessive sweating, which was accompanied in
one case by nausea. One patient complained of headaches
during the placebo treatment period.
pierced, indicating no significant difference between the
two drugs on the basis of the 5 principal criteria for
assessment (P<0,05). Fifteen patients had received Orudis
as the first medication and 14 had received salicylate as
the first medication.
Omdis versus Paracetamol
Significance probability 20: = 0.1
DISCUSSION
Fig. 3. Sequential analysis. Orudis v. salicylate. There is
no appreciable difference between the responses to these
two drugs (P<0,05).
Orudis and salicylate showed superior effectiveness over
each other in an equal number of cases (Il patients each);
in the remaining 7 patients there was no difference in
response during the two treatment periods. Subjective
preferences, however, favoured Orudis in 17 cases, salicy-
late in 10, and neither drug in 2 instances.
Nine patients developed side-effects while on Orudis; 4
had some degree of nausea and 2 had moderately severe
dyspepsia. Seventeen patients experienced side-effects while
receiving salicylates; 6 of these had gastro-intestinal symp-
toms, and 3 complained of tinnitus or deafness.
Purely objective criteria for the assessment of the patient's
response to the treatment of a painful osteo-arthritis are
not only difficult to attain but may be quite unrealistic
as a practical guide to therapy. A diminished awareness
of pain will favourably influence such objective para-
meters as stiffness, and even muscular power, while the
most impressive response to medication may be mitigated
by the occurrence of intolerable side-effects.
In the present trial more weight was given to over-all'
responses than to isolated changes, and in addition the
patients' personal preferences were recorded without
critical analysis. The results suggest that Orudis has
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Fig. 2. Sequential analysis. Orudis v. paracetamol. There
is a strong trend in favour of Orudis, though this does not
reach statistical significance (0,1>P>0,05).
This section of the trial was continued through a total
of 42 patients, at which point a break-through occurred
on the sequential analysis chart in favour of Orudis, but
with a reduced significance probability (Fig. 2).
Significance probability 2:% = 0.2
After 29 patients had completed this part ~f the trial,
the central barrier of the sequential analysis chart was
Omdis versus Acetylsalicylic Acid
This indicated that there was a trend in favour of
Orudis, though this did not achieve statistical significance
(0, I >P>0,05). In 20 cases Orudis was taken during the
first week, and in 22 cases paracetamol was taken first.
The patients' subjective preferences in this section of
the trial paralleled the investigator's preference almost
exactly; 25 preferred Orudis, 12 preferred paracetamol,
and 5 expressed no particular preference.
Eight patients complained of side-effects while receiving
Orudis. Usually this consisted of mild dizziness or tired-
ness; 2 patients experienced nausea and 2 had slight
dyspepsia. Eleven patients had side-effects while on para-
cetamol; among the complaints were headaches (2 cases),
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TABLE Ill. NUMBER OF PATIENTS SHOWING A REDUCTION
IN JOINT CIRCUMFERENCE AFTER TREATMENT WITH
ORUDIS OR SALICYLATE
(Table Ill): while this occurred also in some patients
after taking paracetamol (3 cases), and even after placebo
(I case) it was uncommon and invariably of small degree.
and similar to those of salicylate in high dosage. The
patients themselves, however, favoured Orudis above
salicylate, doubtless because the efficacy of the latter was
10 some extent offset by its unpleasant side-effects.
AllOgether 21 of the 98 patients complained of side-
effects while being treated with Orudis (Table II). In
only 5 cases, however, were these described as severe: i
patient complained of excessive drowsiness, and 1 of
profuse sweating, 1 of dizziness and 2 of dyspepsia.
In no case did these symptoms cause the patient to stop
taking Orudis.
TABLE 11. SIDE-EFFECTS OF ORUDIS (98 PATIENTS)
Response to treatment
Reduced joint size after first week
of treatment








It still remains to be shown whether the superior
therapeutic effects of salicylate and Orudis are due to
anti-inflammatory activity or to purely analgesic activity.
Both drugs appeared to be capable of reducing knee-joint



















It is probable, therefore, that the effect of Orudis in
osteo-arthritis of the knee is due, at least in part, to
anti-inflammatory activity, and this would account for
its superior behaviour over a simple analgesic like
paracetamol.
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